About
Pedro J. Beltran, PhD, is Chief Executive Officer of BridgeBio Oncology Therapeutics (BBOT), effective April 20, 2026, after previously serving as the company's Chief Scientific Officer. He joined BridgeBio Pharma in 2020 as Senior Vice President of Biology and previously held senior oncology research roles at UNITY Biotechnology and Amgen. His background is in oncology drug discovery and translational development, with multiple IND filings, 50+ peer-reviewed publications, conference presentations, and patents.
Areas of interest
biotechoncologyprecision oncologydrug discoveryRAS-pathway cancersPI3Ka biologytranslational medicine